Mabion (WSE:MAB) Second Quarter 2024 Results
Key Financial Results
- Revenue: zł29.8m (down 17% from 2Q 2023).
- Net income: zł10.3m (down 33% from 2Q 2023).
- Profit margin: 35% (down from 42% in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Mabion Earnings Insights
Looking ahead, revenue is expected to decline by 4.2% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Europe are expected to grow by 19%.
Performance of the market in Poland.
The company's shares are down 7.5% from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 3 warning signs for Mabion (2 are a bit unpleasant) you should be aware of.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About WSE:MAB
Mabion
A biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland.
Flawless balance sheet low.
